Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT

Jonathan R Young, Heidi Coy, Michael Douek, Pechin Lo, James Sayre, Allan J. Pantuck, Steven S. Raman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.

Original languageEnglish (US)
Pages (from-to)1911-1918
Number of pages8
JournalAbdominal Radiology
Volume42
Issue number7
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Cell Differentiation
Health Insurance Portability and Accountability Act
Research Ethics Committees
Retrospective Studies
Kidney

Keywords

  • Multidetector computed tomography
  • Renal cell carcinoma
  • Type 1 papillary renal cell carcinoma
  • Type 2 papillary renal cell carcinoma

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Cite this

Type 1 papillary renal cell carcinoma : differentiation from Type 2 papillary RCC on multiphasic MDCT. / Young, Jonathan R; Coy, Heidi; Douek, Michael; Lo, Pechin; Sayre, James; Pantuck, Allan J.; Raman, Steven S.

In: Abdominal Radiology, Vol. 42, No. 7, 01.07.2017, p. 1911-1918.

Research output: Contribution to journalArticle

Young, Jonathan R ; Coy, Heidi ; Douek, Michael ; Lo, Pechin ; Sayre, James ; Pantuck, Allan J. ; Raman, Steven S. / Type 1 papillary renal cell carcinoma : differentiation from Type 2 papillary RCC on multiphasic MDCT. In: Abdominal Radiology. 2017 ; Vol. 42, No. 7. pp. 1911-1918.
@article{9c86de0ea3b648ffac10255119482ced,
title = "Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT",
abstract = "Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73{\%} (36/49), sensitivity of 87{\%} (26/30), positive predictive value of 74{\%} (26/35), and negative predictive value of 71{\%} (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.",
keywords = "Multidetector computed tomography, Renal cell carcinoma, Type 1 papillary renal cell carcinoma, Type 2 papillary renal cell carcinoma",
author = "Young, {Jonathan R} and Heidi Coy and Michael Douek and Pechin Lo and James Sayre and Pantuck, {Allan J.} and Raman, {Steven S.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s00261-017-1091-x",
language = "English (US)",
volume = "42",
pages = "1911--1918",
journal = "Abdominal Radiology",
issn = "2366-004X",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Type 1 papillary renal cell carcinoma

T2 - differentiation from Type 2 papillary RCC on multiphasic MDCT

AU - Young, Jonathan R

AU - Coy, Heidi

AU - Douek, Michael

AU - Lo, Pechin

AU - Sayre, James

AU - Pantuck, Allan J.

AU - Raman, Steven S.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.

AB - Purpose: To investigate whether multiphasic MDCT enhancement can help differentiate type 1 papillary renal cell carcinoma (RCC) from type 2 papillary RCC. Methods: With IRB approval for this HIPAA-compliant retrospective study, we derived a cohort of 36 type 1 papillary RCCs and 33 type 2 papillary RCCs with preoperative multiphasic MDCT with up to four phases (unenhanced, corticomedullary, nephrographic, and excretory) from 2000 to 2013. Following segmentation, a computer-assisted detection (CAD) algorithm selected a 0.5 cm-diameter region of maximal attenuation within each lesion in each phase; a 0.5 cm-diameter region of interest was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as [(Lesion attenuation−cortex attenuation)/cortex attenuation] × 100. Absolute and relative attenuation values were compared using Mann–Whitney tests with Bonferroni correction for multiple comparisons. Results: Relative excretory phase attenuation of type 2 papillary RCCs was significantly greater than that of type 1 papillary RCCs (2.0 vs. −18.3, p = 0.005). Relative excretory phase attenuation differentiated type 1 papillary RCCs from type 2 papillary RCCs with an accuracy of 73% (36/49), sensitivity of 87% (26/30), positive predictive value of 74% (26/35), and negative predictive value of 71% (10/14). Conclusion: Multiphasic MDCT enhancement may assist in differentiating type 1 papillary RCCs from type 2 papillary RCCs, if prospectively validated.

KW - Multidetector computed tomography

KW - Renal cell carcinoma

KW - Type 1 papillary renal cell carcinoma

KW - Type 2 papillary renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85014531180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014531180&partnerID=8YFLogxK

U2 - 10.1007/s00261-017-1091-x

DO - 10.1007/s00261-017-1091-x

M3 - Article

C2 - 28265706

AN - SCOPUS:85014531180

VL - 42

SP - 1911

EP - 1918

JO - Abdominal Radiology

JF - Abdominal Radiology

SN - 2366-004X

IS - 7

ER -